Tomoya Fukui Selected Research

amrubicin

1/2021	Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320).
1/2020	Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer.
10/2018	Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study.
1/2018	Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status.
1/2018	Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
10/2017	Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer.
8/2015	Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer.
6/2012	Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer.
10/2010	Amrubicin for treating elderly and poor-risk patients with small-cell lung cancer.
9/2009	Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tomoya Fukui Research Topics

Disease

27	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 10/2006
12	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020 - 11/2007
9	Neoplasms (Cancer) 01/2021 - 03/2010
6	Neoplasm Metastasis (Metastasis) 02/2019 - 05/2007
6	Lung Neoplasms (Lung Cancer) 02/2019 - 05/2007
4	Interstitial Lung Diseases (Interstitial Lung Disease) 02/2019 - 03/2010
4	Adenocarcinoma of Lung 11/2018 - 12/2008
3	Diarrhea 03/2010 - 05/2007
2	Disease Progression 01/2019 - 01/2019
2	Pneumothorax 05/2017 - 01/2017
2	Chronic Obstructive Pulmonary Disease (COPD) 01/2017 - 04/2011
2	Neutropenia 06/2012 - 05/2007
2	Adenocarcinoma 04/2011 - 11/2007
1	Brain Neoplasms (Brain Tumor) 12/2020
1	Radiation Pneumonitis 01/2020
1	Vomiting 11/2019
1	Nausea 11/2019
1	Vascular Diseases (Vascular Disease) 01/2018
1	Sarcoma (Soft Tissue Sarcoma) 01/2017
1	Leukopenia 08/2015
1	Erysipelas 08/2015
1	Infections 08/2015
1	Malaria 03/2015
1	Carcinogenesis 09/2013
1	Inflammation (Inflammations) 09/2013
1	Metaplasia 07/2013
1	Hyperplasia 07/2013
1	Exanthema (Rash) 03/2010
1	Carcinoma (Carcinomatosis) 09/2009
1	Multiple Myeloma 06/2009

Drug/Important Bio-Agent (IBA)

13	ErbB Receptors (EGF Receptor)IBA 01/2022 - 10/2006
10	amrubicinIBA 01/2021 - 09/2009
7	Tyrosine Kinase InhibitorsIBA 01/2020 - 10/2006
6	Gefitinib (Iressa)FDA Link 03/2010 - 10/2006
5	Irinotecan (Camptosar)FDA LinkGeneric 06/2012 - 05/2007
4	osimertinibIBA 01/2022 - 01/2019
4	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021 - 10/2006
4	Pharmaceutical PreparationsIBA 12/2020 - 03/2010
3	Carboplatin (JM8)FDA LinkGeneric 01/2018 - 02/2009
2	Anaplastic Lymphoma KinaseIBA 01/2021 - 01/2019
2	CrizotinibIBA 01/2021 - 01/2019
2	Biomarkers (Surrogate Marker)IBA 11/2020 - 01/2019
2	Cisplatin (Platino)FDA LinkGeneric 11/2019 - 05/2007
2	NivolumabIBA 01/2019 - 11/2018
2	PlatinumIBA 01/2018 - 01/2018
2	130-nm albumin-bound paclitaxelIBA 01/2018 - 01/2018
2	Pemetrexed (MTA)FDA Link 05/2017 - 01/2016
2	Biological ProductsIBA 11/2013 - 09/2009
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	alectinibIBA 01/2021
1	AfatinibIBA 12/2020
1	AntibodiesIBA 11/2020
1	PerforinIBA 11/2020
1	durvalumabIBA 01/2020
1	ProdrugsIBA 11/2019
1	Neurokinin-1 Receptor AntagonistsIBA 11/2019
1	Palonosetron (Aloxi)FDA Link 11/2019
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2019
1	Alanine Transaminase (SGPT)IBA 01/2019
1	Immune Checkpoint InhibitorsIBA 11/2018
1	B7-H1 AntigenIBA 11/2018
1	Hormones (Hormone)IBA 05/2018
1	AsbestosIBA 01/2018
1	nedaplatinIBA 01/2018
1	Antineoplastic Agents (Antineoplastics)IBA 01/2018
1	Etoposide (VP 16)FDA LinkGeneric 01/2018
1	CollagenIBA 01/2018
1	Folic Acid AntagonistsIBA 05/2017
1	pazopanib FDA Link 01/2017
1	Epidermal Growth Factor (EGF)IBA 01/2017
1	SodiumIBA 03/2016
1	Chloroquine (Aralen)FDA LinkGeneric 03/2015
1	CytokinesIBA 09/2013
1	SecretoglobinsIBA 07/2013
1	Type 1 Angiotensin ReceptorIBA 02/2013
1	P-SelectinIBA 02/2013
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2013
1	Angiotensin IIIBA 02/2013
1	Topoisomerase I InhibitorsIBA 06/2012
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 06/2012
1	Topoisomerase II InhibitorsIBA 06/2012
1	SmokeIBA 04/2011
1	CathepsinsIBA 04/2011
1	Cystatin AIBA 04/2011
1	Phosphotransferases (Kinase)IBA 03/2010
1	Warfarin (Coumadin)FDA LinkGeneric 08/2009
1	GlucocorticoidsIBA 06/2009
1	Paclitaxel (Taxol)FDA LinkGeneric 02/2009
1	GlucuronidaseIBA 10/2008

Therapy/Procedure

14	Drug Therapy (Chemotherapy) 01/2020 - 02/2009
9	Therapeutics 01/2021 - 12/2008
2	Chemoradiotherapy 01/2020 - 07/2017
1	Drug Tapering 12/2020
1	Immunotherapy 11/2020
1	Intravenous Administration 11/2019
1	Cranial Irradiation 01/2018
1	Radiotherapy 03/2016
1	Combined Modality Therapy 03/2016
1	Palliative Care (Palliative Therapy) 06/2014